Argenx Se (ARGX) has released an update.
argenx SE, an immunology company, has reported robust financial results for the first half of 2024, including $478 million in global net product sales for the second quarter. The company is on track with its ‘Vision 2030’ to expand its treatment reach, having launched VYVGART Hytrulo for CIDP in the U.S. and advancing its pipeline with multiple candidates in various stages of development. These milestones underscore argenx’s commitment to transforming autoimmune disease treatment and indicate a strong position for continued growth.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
